Glitch Left Chinese Heparin Plant Uninspected

Law360, New York (February 19, 2008, 12:00 AM EST) -- A Chinese factory responsible for producing the lead ingredient in heparin, a blood-thinning drug that was recently tied to four deaths and hundreds of allergic reactions, hadn't been checked by the U.S. Food & Drug Administration because the agency had confused the names of two different factories.

When the company that made the active ingredient for heparin applied for FDA approval, the agency mistook it for a different company that had already been inspected, the FDA said on Monday.

“To date this is an isolated situation,...
To view the full article, register now.